<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
      version="3.7"
      xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-7.xsd">
   <titleInfo>
      <title>Data on the relationship between lamotrigine and levetiracetam serum/plasma levels and toxicity: Experience at an academic medical center</title>
   </titleInfo>
   <name type="personal" usage="primary">
      <namePart type="given">Kelly E.</namePart>
      <namePart type="family">Wood</namePart>
      <displayForm>Wood, Kelly E.</displayForm>
      <affiliation>Stead Family Department of Pediatrics, University of Iowa Stead Family Children's Hospital, Iowa City, IA 52242, USA</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Kendra L.</namePart>
      <namePart type="family">Palmer</namePart>
      <displayForm>Palmer, Kendra L.</displayForm>
      <affiliation>Department of Pathology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, C-671 GH, Iowa City, IA 52242, USA</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Matthew D.</namePart>
      <namePart type="family">Krasowski</namePart>
      <displayForm>Krasowski, Matthew D.</displayForm>
      <affiliation>Department of Pathology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, C-671 GH, Iowa City, IA 52242, USA</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <typeOfResource>text</typeOfResource>
   <genre>article</genre>
   <originInfo>
      <dateIssued encoding="w3cdtf" keyDate="yes">2021-12</dateIssued>
   </originInfo>
   <language>
      <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
      <languageTerm type="text">English</languageTerm>
   </language>
   <abstract>Lamotrigine and levetiracetam are second-generation anti-epileptic drugs used for the management of seizure disorders and some other medical conditions. In the related research article using retrospective data from an academic medical center, we analyzed 5046 samples originating from 1930 unique patients that had lamotrigine drug levels performed on serum/plasma and 4359 samples from 2451 patients that had levetiracetam drug levels performed. The data in this article provides the patient demographic, clinical location at time of drug level, and specific lamotrigine or levetiracetam serum/plasma drug level for all patients. For those instances with lamotrigine drug level greater than 14.0 mg/L or levetiracetam drug level of 80 mg/L or higher, additional data from chart review includes: indication for ordering the drug level, two main presenting signs or symptoms at time of drug level, timing of drug level (random, trough, peak, or unknown), changes in drug dosing following the drug level, concomitant therapy with valproic acid (lamotrigine only), and details related to drug overdose (if applicable). The analyzed data is provided in the supplementary tables included in this article. Volumes of test ordering by year is included in a figure. The dataset reported is related to the research article entitled “Correlation of Elevated Lamotrigine and Levetiracetam Serum/Plasma Levels with Toxicity: A Long-Term Retrospective Review at an Academic Medical Center” [K. E. Wood, K. L. Palmer, M.D. Krasowski, Correlation of elevated lamotrigine and levetiracetam serum/plasma levels with toxicity: A long-term retrospective review at an academic medical center, Toxicol. Rep. (2021) 8:1592-1598] </abstract>
   <subject>
      <topic>Cardiotoxicity</topic>
   </subject>
   <subject>
      <topic>Drug monitoring</topic>
   </subject>
   <subject>
      <topic>Lamotrigine</topic>
   </subject>
   <subject>
      <topic>Levetiracetam</topic>
   </subject>
   <subject>
      <topic>Neurotoxicity syndromes</topic>
   </subject>
   <subject>
      <topic>Pharmacokinetics</topic>
   </subject>
   <relatedItem type="host">
      <titleInfo>
         <title>Data in Brief</title>
      </titleInfo>
      <originInfo>
         <publisher>Elsevier Inc.</publisher>
      </originInfo>
      <identifier type="issn">2352-3409</identifier>
      <part>
         <detail type="volume">
            <number>39</number>
            <caption>v.</caption>
         </detail>
         <text type="display-date">December 2021</text>
         <text type="year">2021</text>
         <text type="month">December</text>
         <extent unit="pages">
            <start>107555</start>
         </extent>
      </part>
   </relatedItem>
   <identifier type="doi">10.1016/j.dib.2021.107555</identifier>
   <location>
      <url>http://dx.doi.org/10.1016/j.dib.2021.107555</url>
   </location>
   <identifier type="pii">S2352-3409(21)00831-3</identifier>
   <accessCondition type="use and reproduction"
                    displayLabel="Creative Commons Attribution 4.0 Generic (CC BY 4.0)">
      <program xmlns="https://data.crossref.org/schemas/AccessIndicators.xsd">
         <licence_ref applies_to="reuse" start_date="2021-11-03"/>
         <licence_ref>http://creativecommons.org/licenses/by/4.0/</licence_ref>
      </program>
   </accessCondition>
   <extension>
      <vendorName/>
      <archiveFile/>
      <originalFile>file:/C:/Users/Carlos.Martinez/OneDrive%20-%20USDA/XML_projects/OpenAccess/OpenAccess/transform/source/sourcefiles/164128545923847224-00001/2352-3409/S2352340921X00066/S2352340921008313/S2352340921008313.xml</originalFile>
      <workingDirectory>C:\Users\Carlos.Martinez\OneDrive - USDA\XML_projects\OpenAccess\OpenAccess\transform\result\</workingDirectory>
   </extension>
</mods>
